i-Base home
Search Menu
  • Home
  • HTB
  • 2002
  • January
  • 09

HTB

9 January 2002

Contents

Conference reports

  • 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 16-19 December 2001
  • Low dose pegylated interferon is ineffective in treating HIV/HCV co-infected patients
  • Phenotypic resistance to ddI is less frequent than resistance to ZDV, 3TC and abacavir
  • Impact of Kaletra on amprenavir plasma concentrations in HIV treatment-experienced patients
  • Immune reconstitution more difficult with low baseline CD4+ T cell counts
  • HIV-1 may revert to less pathogenic strain a few days after starting HAART
  • Change from CCR5 to CXCR4 phenotype may affect immunologic responses
  • ddI EC (Videx) study confirms and clarifies dosing on an empty stomach
  • Swatch study: should we be cycling drugs?
  • New HIV drugs, resistance, pharmacogenomics
  • Antiretroviral therapy
  • Immunopathogenesis of HIV infection

Basic science and immunology

  • New findings explain T-cell loss in HIV infection

Other news

  • Voluntary suspension of Kava-kava sales following safety concerns
  • The Chapman Clinic: musculoskeletal treatment for patients with HIV

On the web

  • Additional reports from ICAAC 2001
  • Double scourge: tuberculosis and HIV coinfection
  • The road to eradication: is HAART hard enough?
  • HTB RSS

Early access

  • No benefit from BRII and GSK monoclonal antibodies in ACTIV-3 study 5 March 2021
  • Chronic kidney disease (CKD) in HIV positive people linked to time with low CD4 count: partly reversible after effective ART 1 March 2021
  • All early access reports

Current issues

  • March 2021
  • February 2021
  • January 2021
  • Back issues

Special report

  • Early results report 90% efficacy with from Pfizer/BioNTech COVID vaccine 11 November 2020

More from HTB

  • Conference reports
  • Conference shortcuts
  • Articles by subject
  • PDFs
  • Subscribe
  • HTB homepage

Home

  • i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

Verify here.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links
HIV positive
Advocate
Professional
Donate
Feedback
Advice and information
Q and A
Phoneline
Pocket info
Guides
HIV meds
Glossary
Research and conference reports
HTB
HTB South
Pipeline report
Publications and resources
Publications
Other resources
Translations
Slide sets
Order and subscribe
News and updates
News
Blogs
Advocates' network
UK-CAB
Training manual
i-Base
About us
Contact
Sitemap
Home
Find us on Facebook